The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …

Animal studies are a foundation for defining mechanisms of atherosclerosis and potential
targets of drugs to prevent lesion development or reverse the disease. In the current …

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
the Management of Blood Cholesterol: Executive Summary: A Report of the American …

The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

The 2021 guidelines primary panel selected clinically relevant questions and produced
updated recommendations, on the basis of important new findings that have emerged since …

Familial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant
disorder that affects% 1 in 220 individuals globally. 1 FH is characterized by lifelong …

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …